Clinical Trial Update: Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update assessing the safety of hV01, a recombinant IL-21–expressing oncolytic vaccinia virus, in patients with advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• hV01 (recombinant human IL-21-expressing oncolytic vaccinia virus)

Snippet

Sponsor: Hangzhou Converd Co., Ltd. | Conditions: Advanced Solid Tumors | Phase 1 | Status: ACTIVE_NOT_RECRUITING